Abstract
We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml, respectively. All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin. Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/ml for ceftriaxone. ETX0914 may be an effective treatment option for gonorrhea.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azithromycin / pharmacology
-
Barbiturates / pharmacology*
-
Ceftriaxone / pharmacology
-
Ciprofloxacin / pharmacology
-
DNA Gyrase / genetics*
-
DNA Gyrase / metabolism
-
Drug Resistance, Multiple, Bacterial / drug effects*
-
Drug Resistance, Multiple, Bacterial / genetics
-
Gene Expression
-
Gonorrhea / microbiology
-
Humans
-
Isoxazoles
-
Male
-
Microbial Sensitivity Tests
-
Morpholines
-
Neisseria gonorrhoeae / drug effects*
-
Neisseria gonorrhoeae / enzymology
-
Neisseria gonorrhoeae / genetics
-
Neisseria gonorrhoeae / isolation & purification
-
Oxazolidinones
-
Spiro Compounds / pharmacology*
-
Tetracycline / pharmacology
-
Topoisomerase II Inhibitors / pharmacology*
-
Urethritis / microbiology
Substances
-
Anti-Bacterial Agents
-
Barbiturates
-
Isoxazoles
-
Morpholines
-
Oxazolidinones
-
Spiro Compounds
-
Topoisomerase II Inhibitors
-
Ciprofloxacin
-
Ceftriaxone
-
Azithromycin
-
DNA Gyrase
-
Tetracycline
-
zoliflodacin